A detailed history of Aqr Capital Management LLC transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 122,515 shares of KURA stock, worth $1.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
122,515
Previous 81,655 50.04%
Holding current value
$1.25 Million
Previous $1.68 Million 42.36%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$18.57 - $23.23 $758,770 - $949,177
40,860 Added 50.04%
122,515 $2.39 Million
Q2 2024

Aug 14, 2024

BUY
$17.53 - $22.98 $1.02 Million - $1.34 Million
58,422 Added 251.46%
81,655 $1.68 Million
Q1 2024

May 15, 2024

SELL
$13.42 - $23.53 $90,678 - $158,992
-6,757 Reduced 22.53%
23,233 $495,000
Q4 2023

Feb 14, 2024

SELL
$7.58 - $14.38 $611,319 - $1.16 Million
-80,649 Reduced 72.89%
29,990 $431,000
Q3 2023

Nov 14, 2023

BUY
$8.44 - $11.86 $816,510 - $1.15 Million
96,743 Added 696.19%
110,639 $1.01 Million
Q2 2023

Aug 14, 2023

BUY
$9.62 - $13.99 $133,679 - $194,405
13,896 New
13,896 $147,000
Q2 2021

Aug 16, 2021

SELL
$20.85 - $29.88 $268,443 - $384,705
-12,875 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$24.75 - $39.14 $65,092 - $102,938
-2,630 Reduced 16.96%
12,875 $364,000
Q4 2020

Feb 16, 2021

BUY
$29.0 - $41.62 $449,645 - $645,318
15,505 New
15,505 $506,000
Q4 2018

Feb 14, 2019

SELL
$10.6 - $17.49 $194,552 - $321,011
-18,354 Closed
0 $0
Q3 2018

Nov 15, 2018

BUY
$16.65 - $21.85 $11,704 - $15,360
703 Added 3.98%
18,354 $321,000
Q2 2018

Aug 14, 2018

SELL
$14.8 - $18.8 $159,159 - $202,175
-10,754 Reduced 37.86%
17,651 $321,000
Q1 2018

May 15, 2018

BUY
$14.5 - $23.4 $411,872 - $664,677
28,405 New
28,405 $533,000

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $682M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.